Treatment of relapsed and refractory myeloma. - Wikidata - awgldk - TriplyDB

Treatment of relapsed and refractory myeloma.

Treatment of relapsed and refractory myeloma.

http://www.wikidata.org/entity/Q37209929

about

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.Second autologous transplant as salvage therapy in multiple myeloma.

P2860

Q34130459-E750B860-26EE-4397-BB72-47FEF9D0EDAB Q38151157-D63B5DB0-FFEC-458F-AAA5-281715C5EAAD

P2860

Treatment of relapsed and refractory myeloma.

http://www.wikidata.org/entity/Q37209929

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Treatment of relapsed and refractory myeloma.

@en

Treatment of relapsed and refractory myeloma.

@nl

type

label

Treatment of relapsed and refractory myeloma.

@en

Treatment of relapsed and refractory myeloma.

@nl

prefLabel

Treatment of relapsed and refractory myeloma.

@en

Treatment of relapsed and refractory myeloma.

@nl

P1433

Q37209929-4CF5F057-0513-4A95-B103-4655BF362A58

P1476

Q37209929-D1626B7F-F79C-40E2-9C5A-5DDF15742778

P2093

Q37209929-196B918F-F590-4AD3-8706-1C8DF9CFEDBD

Q37209929-27302583-0293-41E2-9ECE-1F35277DD713

Q37209929-32CB456C-7CE8-4BDD-B3E3-07FBCEB842F9

Q37209929-4125E270-EFB8-411C-A432-05CDDBAFA1E6

Q37209929-466C7E72-FF8B-4E77-A233-2CA655263AC0

Q37209929-5355715F-FFD4-494B-9C6B-76CB43B46E67

Q37209929-56FF762C-2D48-44F5-A35F-A65CABCDC9CA

Q37209929-CFFEF977-21F8-4F08-9498-6321AE3D9F95

Q37209929-DBCC1D06-7A50-40E5-9970-7CE589CC1A0F

P2860

Q37209929-0056A9C7-E704-40FA-82E6-D0DFFF33B819

Q37209929-026D9130-E9A8-4526-8F08-005C7279C601

Q37209929-040BE636-A828-4A8E-A3F7-68691ABD2E46

Q37209929-0B095F9E-111B-45CB-87CD-3BE58684FD95

Q37209929-0BE6430E-6C99-45D5-9413-E2EA6AA3A5C6

Q37209929-19377638-2FBB-4391-883A-40D979A16B61

Q37209929-204B927B-5E53-4963-B449-289BEEB6C121

Q37209929-21F65B40-D1F8-4174-83C5-998927A6D21F

Q37209929-2503B3FF-97AD-4DE7-B0AA-16795C518F51

Q37209929-26FEB790-A869-4EA2-97AB-0A964283906D

P304

Q37209929-923BC81B-26A3-43C8-A14A-8C1A079519DE

P31

Q37209929-4E630B5C-D5A1-410C-9F65-9BAB3B086455

P356

Q37209929-0D32BD3B-FC21-4FA0-B50B-D35EF3EE7814

P433

Q37209929-091B243C-E6C5-4023-81E7-27C4E40E811E

P478

Q37209929-3132C30A-CE8C-4C73-984A-8EAE8F9C8AA2

P577

Q37209929-764C6D2C-780F-4ECD-B40A-6449033ACBFB

P698

Q37209929-6A09CC8D-35ED-40DF-BE60-934A2A2D1E18

P356

10428190802064941

P1433

Leukemia & Lymphoma

P1476

Treatment of relapsed and refractory myeloma.

@en

P2093

Andrew R Belch

http://www.w3.org/2001/XMLSchema#string

Darrell White

http://www.w3.org/2001/XMLSchema#string

Donna E Reece

http://www.w3.org/2001/XMLSchema#string

Harold Atkins

http://www.w3.org/2001/XMLSchema#string

Heather A Leitch

http://www.w3.org/2001/XMLSchema#string

Leah A Canning

http://www.w3.org/2001/XMLSchema#string

Michael J Kovacs

http://www.w3.org/2001/XMLSchema#string

Michael Voralia

http://www.w3.org/2001/XMLSchema#string

Richard LeBlanc

http://www.w3.org/2001/XMLSchema#string

P2860

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.

A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.

P304

1470-1485

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428190802064941

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18608859

http://www.w3.org/2001/XMLSchema#string